Amicus Therapeutics Inc (FOLD) Files Form 4 Insider Selling : William D Iii Baird Sells 20,500 Shares

Amicus Therapeutics Inc (FOLD): William D Iii Baird , Chief Financial Officer of Amicus Therapeutics Inc sold 20,500 shares on Sep 20, 2016. The Insider selling transaction was reported by the company on Sep 22, 2016 to the Securities and Exchange Commission. The shares were sold at $8.00 per share for a total value of $164,074.80 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 8, 2016, Hung Do (Chief Science Officer) sold 25,000 shares at $7.00 per share price.On Aug 8, 2016, Jay Barth (Chief Medical Officer) sold 10,458 shares at $7.00 per share price.Also, On Jun 6, 2016, Ellen Rosenberg (General Counsel & Corp. Secy) purchased 15,000 shares at $7.67 per share price.On Nov 10, 2015, Margaret G Mcglynn (director) purchased 10,000 shares at $10.27 per share price.

Amicus Therapeutics: On Tuesday, Sep 21, 2016 heightened volatility was witnessed in Amicus Therapeutics which led to swings in the share price. The shares opened for trading at $7.72 and hit $8.35 on the upside , eventually ending the session at $7.89, with a gain of 3.27% or 0.25 points. The heightened volatility saw the trading volume jump to 46,65,166 shares. The 52-week high of the share price is $17.93 and the company has a market cap of $1,121 M . The 52-week low of the share price is at $4.98.

Amicus Therapeutics Money Flow Index Chart

Amicus Therapeutics Inc. is a biopharmaceutical company. The Company focuses on the discovery development and commercialization of medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold) a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs including Fabry disease Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease SD-101 for Epidermolysis Bullosa (EB) as well as ERT products for Fabry disease Pompe disease and MPS I.

Leave a Reply

Amicus Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amicus Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.